BioCentury | Jun 20, 2020

Clinical scorecard for COVID-19: lessons from the first wave of controlled trials

Breaking through the noise of poor-quality clinical studies are the first clear signals of a treatment paradigm for COVID-19, indicating how and when to use the two major therapeutic approaches -- attacking the virus and...
BC Innovations | Nov 19, 2019
Distillery Therapeutics

Combining Arava with HIF1A inhibition to treat RA

DISEASE CATEGORY: Autoimmune disease INDICATION: Rheumatoid arthritis (RA) Inhibiting HIF1A could enhance the efficacy of Arava leflunomide for RA-associated bone erosion in patients with high C-reactive protein levels. In a rat model of RA, Arava...
BC Innovations | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Blocking pyrimidine synthesis via inhibition of CAD or DHODH, an enzyme downstream CAD, could treat glioblastoma. In patients, high tumor expression of a pyrimidine metabolism gene signature was associated...
BC Innovations | May 20, 2019
Distillery Therapeutics

Aubagio and other DHODH inhibitors as epilepsy therapies

DISEASE CATEGORY: Neurology INDICATION: Epilepsy Patient sample, cell culture and mouse studies suggest inhibiting DHODH could help treat epilepsy. Metabolic modeling of transcriptome data from the cortex and hippocampus of epilepsy patients and two rat...
BC Innovations | Apr 10, 2018
Distillery Therapeutics


INDICATION: Melanoma Cell culture and mouse studies identified p53-activating tetrahydroindazole-based DHODH inhibitors that could help treat melanoma. Screening of a small molecule library in human melanoma cell line-based assays of p53-dependent transcription, followed by chemical...
BioCentury | Apr 14, 2017
Emerging Company Profile

Tolerating DHODH

Immunic AG is betting on the tolerability and efficacy of its oral, next-generation dihydroorotate dehydrogenase inhibitor to differentiate it from first-generation agents and give it an edge over other types of oral therapies in the...
BC Innovations | Feb 16, 2017
Emerging Company Profile

Autoimmunity alternative

Inhibiting the nucleotide biosynthetic pathway in autoimmune diseases is one way to avoid the risks of broad immunosuppression, but the marketed compounds have serious side effects of their own. Step Pharma is pursuing a safer...
BC Innovations | Oct 20, 2016
Distillery Therapeutics


INDICATION: Acute myelogenous leukemia (AML) Mouse studies suggest inhibiting DHODH could help treat acute AML. In two mouse models of AML, a DHODH inhibitor tool compound increased survival and the levels of markers of differentiation...
BC Week In Review | May 9, 2016
Clinical News

PRTX-100: Preliminary Phase I/II data

Preliminary data from 8 patients with active RA in the per protocol (PP) population of part 1 of the 2-part, open-label, U.S. Phase I/II SPARTA-II (PRTX-100-105) trial showed that IV PRTX-100 for 6 months reduced...
BC Week In Review | Oct 19, 2015
Company News

Sanofi sales and marketing update

Sanofi launched in the U.S. an authorized generic version of its Arava leflunomide to treat rheumatoid arthritis (RA). The pyrimidine synthesis inhibitor has a wholesale acquisition cost (WAC) of $5 per 10 mg tablet. The...
Items per page:
1 - 10 of 55